Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by...

Area of Science:

• Nephrology
• Cardiovascular Biology
• Inflammation Research

Background:

• Dialysis patients with end-stage renal disease often experience chronic microinflammation, cytokine dysregulation, and endothelial dysfunction, contributing to cardiovascular disease (CVD) and mortality.
• Novel hemodialysis filters aim to mitigate these complications by improving toxin removal and reducing inflammatory burden.

Purpose of the Study:

• To investigate the impact of novel medium cut-off (MCO) hemodialysis membranes compared to high-flux (HF) membranes on systemic microinflammation, uremia, and endothelial dysfunction.
• To elucidate the role of tumor necrosis factor-alpha (TNF-α) signaling in uremia-induced endothelial maladaptation and its modulation by MCO membranes.

Main Methods:

• Human endothelial cells (ECs) were exposed to uremic serum from patients undergoing hemodialysis with either HF or MCO membranes (PERCI-II trial).
• VEGF production, angiogenesis, and cytokine profiles were assessed. The specific role of TNF-α and its signaling pathways (AP-1/c-FOS) in endothelial dysfunction was analyzed.

Main Results:

• Dialysis with MCO membranes significantly reduced proinflammatory mediators compared to HF membranes.
• MCO membranes led to decreased endothelial VEGF production and angiogenesis.
• TNF-α signaling was identified as a key mediator of uremia-induced endothelial maladaptation, with MCO membranes showing a positive modulatory effect.

Conclusions:

• Uremic toxins, especially TNF-α, drive endothelial maladaptation, VEGF expression, and aberrant angiogenesis in dialysis patients.
• Novel MCO hemodialysis membranes offer a promising therapeutic strategy to positively modulate these detrimental processes, potentially improving cardiovascular outcomes in dialysis patients.